|
|
News Breaks | | | | January 7, 2013 | | 08:19 EDT |  | VVUS | VIVUS says Qsymia prescriptions shipped rise to 12,978 for 4 weeks end Dec. 21
VIVUS disclosed in a regulatory filing that prescriptions shipped to patients for its weight loss drug Qsymia rose to 12,978 for the four weeks ending Dec. 21, 12 from 7,749 for the four weeks ending Nov. 23, 12. The company also upwardly revised its estimate for total prescriptions shipped for the four weeks ending Oct. 26, 2012 to 5,394 from the previously reported 4,904, stating that the adjustment is based on additional information provided from a certified prescribing pharmacy. The company said the data on Qsymia prescriptions shipped to patients is derived from data made available to the company from third parties and due to this and other factors, the data reported may be subject to adjustment should the company receive adjusted information from these third parties. VIVUS noted that on November 19, 2012, the company initiated the "Qsymia Get Started! Free Trial Offer Program" in two certified pharmacies and a third certified pharmacy began participating in this program in late December 2012. According to this program, the company is, for a limited time, offering to eligible patients a 14-capsule starting dose of Qsymia, 3.75 mg/23 mg, at no charge to the patient. After initiation of the program a significant portion of the prescriptions at the 3.75 mg/23 mg dose level were shipped at no charge from the participating certified pharmacies to the patient under this program. In pre-market trading, shares of VIVUS rose about 9.7% to $15.08. | |
|
News For VVUS From The Last 14 Days Check below for free stories on VVUS the last two weeks. |
|
|
| May 14, 2013 | | 10:01 EDT |  | VVUS | On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AVG Technologies (AVG) downgraded to Neutral from Buy at Goldman... Cigna (CI) downgraded to Hold from Buy at Jefferies... Cree (CREE) downgraded to Neutral from Buy at Sterne Agee... Melco Crown (MPEL) downgraded to Neutral from Buy at UBS... SolarCity (SCTY) downgraded to Neutral from Buy at Roth Capital... KB Home (KBH) downgraded to Market Perform from Outperform at Raymond James... Ryland Group (RYL) downgraded to Underperform from Market Perform at Raymond James... Alere (ALR) downgraded to Hold from Buy at Craig-Hallum... Evolution Petroleum (EPM) downgraded to Hold from Buy at MLV Equity... Oil States (OIS) downgraded to Hold from Buy at BB&T... VIVUS (VVUS) downgraded to Neutral from Buy at Lazard Capital. | | | 07:33 EDT | | VVUS | VIVUS downgraded to Neutral from Buy at Lazard Capital
 Subscribe for More Information | | | May 13, 2013 | | 07:41 EDT | | VVUS | VIVUS mails letter to stockholders providing business update
Subscribe for More Information | | | May 8, 2013 | | 07:35 EDT |  | VVUS | VIVUS reports Q1 EPS (53c), consensus (51c)
Reports Q1 revenue $4.11M, consensus $5.22M. | | | May 7, 2013 | | 16:52 EDT | | VVUS | First Manhattan Co. releases case for full board change at VIVUS
Subscribe for More Information | |
|
|
|
|
|
|
